Abstract:BACKGROUND: In a randomized trial, the early introduction of peanuts in infants at high risk for allergy was shown to prevent peanut allergy. In this follow-up study, we investigated whether the rate of peanut allergy remained low after 12 months of peanut avoidance among participants who had consumed peanuts during the primary trial (peanut-consumption group), as compared with those who had avoided peanuts (peanut-avoidance group).METHODS: At the end of the primary trial, we instructed all the participants to avoid peanuts for 12 months. The primary outcome was the percentage of participants with peanut allergy at the end of the 12-month period, when the participants were 72 months of age.RESULTS: We enrolled 556 of 628 eligible participants (88.5%) from the primary trial; 550 participants (98.9%) had complete primary-outcome data. The rate of adherence to avoidance in the follow-up study was high (90.4% in the peanut-avoidance group and 69.3% in the peanut-consumption group). Peanut allergy at 72 months was significantly more prevalent among participants in the peanut-avoidance group than among those in the peanut-consumption group (18.6% [52 of 280 participants] vs. 4.8% [13 of 270], P<0.001). Three new cases of allergy developed in each group, but after 12 months of avoidance there was no significant increase in the prevalence of allergy among participants in the consumption group (3.6% [10 of 274 participants] at 60 months and 4.8% [13 of 270] at 72 months, P=0.25). Fewer participants in the peanut-consumption group than in the peanut-avoidance group had high levels of Ara h2 (a component of peanut protein)-specific IgE and peanut-specific IgE; in addition, participants in the peanut-consumption group continued to have a higher level of peanut-specific IgG4 and a higher peanut-specific IgG4:IgE ratio.CONCLUSIONS: Among children at high risk for allergy in whom peanuts had been introduced in the first year of life and continued until 5 years of age, a 12-month period of peanut avoidance was not associated with an increase in the prevalence of peanut allergy. Longer-term effects are not known. (Funded by the National Institute of Allergy and Infectious Diseases and others; LEAP-On ClinicalTrials.gov number, NCT01366846.).

Eating peanuts in early years reduces allergy risk even with later abstinence.

Effect of Avoidance on Peanut Allergy after Early Peanut Consumption

Early Introduction of Food Allergens and Risk of Developing Food Allergy

Early Peanut Introduction in Primary Care: Evaluation of a Multicomponent Intervention

Peanut immunotherapy provides long lasting suppression of allergy, finds study

Optimising the management of peanut allergy by targeting immune plasticity

Rates of New Peanut Allergy and Discontinuation Following Introduction in High-Risk Infants

Risk subgroups and intervention effects among infants at high risk for peanut allergy: A model for clinical decision making

Air pollution is associated with persistent peanut allergy in the first 10 years

Impact of peanut consumption in the LEAP Study: Feasibility, growth, and nutrition

Peanut allergy in toddlers

Peanut Allergy in Children—Is Prevention Better than Cure?

Dietary exposures and allergy prevention in high-risk infants

Early Peanut Introduction Awareness, Beliefs, and Practices Among Parents and Caregivers

Epitope-Specific IgE at 1 Year of Age Can Predict Peanut Allergy Status at 5 Years

Successful introduction of peanut in sensitized infants with reported reactions at home

Consensus communication on early peanut introduction and the prevention of peanut allergy in high-risk infants

The Protective Effect of Moderate Maternal Peanut Consumption on Peanut Sensitization and Allergy

[ALLERGY PREVENTION AND TREATMENT DURING THE FIRST YEAR]

Early-life Risk Factors for Food Allergy: Dietary and Environmental Factors Revisited.

Oral mucosa effectively protects against peanut allergy in mice